These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 26673798)

  • 21. Suspected recurrence of brain metastases after focused high dose radiotherapy: can [
    Romagna A; Unterrainer M; Schmid-Tannwald C; Brendel M; Tonn JC; Nachbichler SB; Muacevic A; Bartenstein P; Kreth FW; Albert NL
    Radiat Oncol; 2016 Oct; 11(1):139. PubMed ID: 27769279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI.
    Werner JM; Stoffels G; Lichtenstein T; Borggrefe J; Lohmann P; Ceccon G; Shah NJ; Fink GR; Langen KJ; Kabbasch C; Galldiks N
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1889-1901. PubMed ID: 31203420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas.
    Lohmann P; Herzog H; Rota Kops E; Stoffels G; Judov N; Filss C; Galldiks N; Tellmann L; Weiss C; Sabel M; Coenen HH; Shah NJ; Langen KJ
    Eur Radiol; 2015 Oct; 25(10):3017-24. PubMed ID: 25813014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [
    Henriksen OM; Hansen AE; Muhic A; Marner L; Madsen K; Møller S; Hasselbalch B; Lundemann MJ; Scheie D; Skjøth-Rasmussen J; Poulsen HS; Larsen VA; Larsson HBW; Law I
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4677-4691. PubMed ID: 35907033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma.
    Kebir S; Schmidt T; Weber M; Lazaridis L; Galldiks N; Langen KJ; Kleinschnitz C; Hattingen E; Herrlinger U; Lohmann P; Glas M
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33105661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
    Tscherpel C; Dunkl V; Ceccon G; Stoffels G; Judov N; Rapp M; Meyer PT; Kops ER; Ermert J; Fink GR; Shah NJ; Langen KJ; Galldiks N
    Neuro Oncol; 2017 May; 19(5):710-718. PubMed ID: 28039366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.
    Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ
    J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience.
    Ceccon G; Lazaridis L; Stoffels G; Rapp M; Weber M; Blau T; Lohmann P; Kebir S; Herrmann K; Fink GR; Langen KJ; Glas M; Galldiks N
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1626-1635. PubMed ID: 29564490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
    Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ
    Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
    Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
    Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Treatment Response Assessment Using
    Ceccon G; Lohmann P; Werner JM; Tscherpel C; Dunkl V; Stoffels G; Rosen J; Rapp M; Sabel M; Herrlinger U; Schäfer N; Shah NJ; Fink GR; Langen KJ; Galldiks N
    J Nucl Med; 2021 Jul; 62(7):918-925. PubMed ID: 33158907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents.
    Dunkl V; Cleff C; Stoffels G; Judov N; Sarikaya-Seiwert S; Law I; Bøgeskov L; Nysom K; Andersen SB; Steiger HJ; Fink GR; Reifenberger G; Shah NJ; Coenen HH; Langen KJ; Galldiks N
    J Nucl Med; 2015 Jan; 56(1):88-92. PubMed ID: 25525183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume.
    Piroth MD; Galldiks N; Pinkawa M; Holy R; Stoffels G; Ermert J; Mottaghy FM; Shah NJ; Langen KJ; Eble MJ
    Radiat Oncol; 2016 Jun; 11():87. PubMed ID: 27342976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of Dexamethasone on O-(2-[
    Stegmayr C; Stoffels G; Kops ER; Lohmann P; Galldiks N; Shah NJ; Neumaier B; Langen KJ
    Mol Imaging Biol; 2019 Feb; 21(1):168-174. PubMed ID: 29845426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
    Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.
    Barry N; Francis RJ; Ebert MA; Koh ES; Rowshanfarzad P; Hassan GM; Kendrick J; Gan HK; Lee ST; Lau E; Moffat BA; Fitt G; Moore A; Thomas P; Pattison DA; Akhurst T; Alipour R; Thomas EL; Hsiao E; Schembri GP; Lin P; Ly T; Yap J; Kirkwood I; Vallat W; Khan S; Krishna D; Ngai S; Yu C; Beuzeville S; Yeow TC; Bailey D; Cook O; Whitehead A; Dykyj R; Rossi A; Grose A; Scott AM
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3970-3981. PubMed ID: 37563351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of
    Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2257-2265. PubMed ID: 28831534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
    Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Maurer GD; Brucker DP; Stoffels G; Filipski K; Filss CP; Mottaghy FM; Galldiks N; Steinbach JP; Hattingen E; Langen KJ
    J Nucl Med; 2020 Apr; 61(4):505-511. PubMed ID: 31519802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.